Genmab A/S Stock

Genmab A/S PEG

The PEG Ratio (Price/Earnings-to-Growth) of Genmab A/S (GMAB.CO) as of Jul 26, 2026 is 2.25. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 1.91 — a change of 18.14% (higher).

PEG

2.25

YoY

18.14%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Genmab A/S is 2026 2.25 . PEG Ratio (Price/Earnings-to-Growth) of Genmab A/S was 2025 1.91 . It decreases by 18.14% higher compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

PEG Ratio (Price/Earnings-to-Growth) of Genmab A/S is 2.25 in 2026.

Access this data via the Eulerpool API

Valuation — Genmab A/S

All Key Metrics — Genmab A/S